KLI

Initial Transarterial Chemoembolization (TACE) Using HepaSpheres 20-40 mu m and Subsequent Lipiodol TACE in Patients with Hepatocellular Carcinoma > 5 cm

Metadata Downloads
Abstract
Purpose: To investigate clinical outcomes of drug-eluting bead transarterial chemoembolization (DEB-TACE) using HepaSpheres 20-40 mu m in diameter and subsequent cisplatin-based lipiodol TACE (Cis-TACE) in patients with hepatocellular carcinoma (HCC) > 5 cm. Materials and Methods: This study included 39 consecutive patients (34 men, 5 women; mean age, 63.5 years; range, 39-80 years) who underwent DEB-TACE using HepaSpheres 20-40 mu m as first-line treatment for HCC > 5 cm (mean diameter, 8.2 cm; range, 5.1-13 cm) between September 2018 and August 2019. Patients with new tumors, residual tumors, or tumor growth after initial DEB-TACE underwent subsequent Cis-TACE. Results: All 39 patients underwent initial DEB-TACE successfully, with 35 (89.7%) and three (7.7%) patients experiencing minor and major complications, respectively. After initial DEB-TACE, one patient (2.6%) achieved complete response (CR), 35 (89.7%) achieved partial response (PR), and three (7.7%) experienced progressive disease (PD). During a median follow-up period of 14.4 months (range, 0.6-23 months), 23 patients underwent Cis-TACE, with 11, three, and nine achieving CR, PR, and PD, respectively. The median overall survival time was 20.9 months (95% confidence interval (CI), 18.6-23.2 months), the median time to progression was 8.8 months (95% CI, 6.5-11.1 months), and the median time to local tumor recurrence was 16 months (95% CI, 7.4-24.6 months). Conclusions: DEB-TACE using HepaSpheres 20-40 mu m in diameter can be a safe and effective initial treatment method in patients with HCC > 5 cm. Subsequent Cis-TACE constitutes a good adjuvant method to enhance tumor response after initial DEB-TACE.
Author(s)
조수민추희호김종우김진형권동일
Issued Date
2021
Type
Article
Keyword
Cis-TACE (cisplatin-based lipiodol transarterial chemoembolization)DEB-TACE (drug-eluting bead transarterial chemoembolization)hepatocellular carcinoma
DOI
10.3390/life11040358
URI
https://oak.ulsan.ac.kr/handle/2021.oak/7358
https://ulsan-primo.hosted.exlibrisgroup.com/primo-explore/fulldisplay?docid=TN_cdi_doaj_primary_oai_doaj_org_article_a3e9566703a5419f9a97dcb0bdabaa97&context=PC&vid=ULSAN&lang=ko_KR&search_scope=default_scope&adaptor=primo_central_multiple_fe&tab=default_tab&query=any,contains,Initial%20Transarterial%20Chemoembolization%20(TACE)%20Using%20HepaSpheres%2020-40%20mu%20m%20and%20Subsequent%20Lipiodol%20TACE%20in%20Patients%20with%20Hepatocellular%20Carcinoma%20%3E%205%20cm&offset=0&pcAvailability=true
Publisher
LIFE-BASEL
Location
스위스
Language
영어
ISSN
2075-1729
Citation Volume
11
Citation Number
11
Citation Start Page
0
Citation End Page
0
Appears in Collections:
Medicine > Medicine
Authorize & License
  • Authorize공개
Files in This Item:
  • There are no files associated with this item.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.